Sun Pharma: Continues to outpace industry - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sun Pharma: Continues to outpace industry

Jul 18, 2000

Sun Pharma continued its good run, outpacing the overall pharmaceutical industry. While the topline shot up by over 28%, the bottomline grew by a mind boggling 55%. During the quarter the amalgamated the operations of Gujarat Lyka by allotting 0.47 m shares in the ratio of 1 share for every 21.33 shares of Gujarat Lyka. If one were to account for the fact that the sales figures for corresponding quarter in the previous year, did not include domestic bulk drug sales of Rs. 61.3 m of Gujarat Lyka, the topline growth comes to around 21.6%, which is still very creditable. The earnings also include the profit of Sun Pharmaceutical Exports, a 99.28% subsidiary of the company which is proposed to be merged with the company with effect from April 2000.

(Rs m) 1QFY00 1QFY01 Change
Sales 1,029 1,327 28.9%
Other Income 4 5 32.4%
Expenditure 782 967 23.6%
Operating Profit (EBDIT) 247 360 45.5%
Operating Profit Margin (%) 24.0% 27.1%  
Interest (net) 7 (3)  
Depreciation 27 38 38.9%
Profit before Tax 217 330 52.0%
Other Adjustments      
Tax 17 20 16.0%
Profit after Tax/(Loss) 200 311 55.1%
Net profit margin (%) 19.5% 23.4%  
No. of Shares (m) (eoy) 15.4 46.7  
Diluted no. of shares (m) 46.7 46.7  
Diluted Earnings per share* 17.1 26.6  
*(annualised)      

Coming to the operations themselves the company is currently ranked 5th by retail prescription sales, up from 10th position last year (ORG Retail Chemist Audit, May 2000 & 1999) . Six of the company's speciality brands feature in the top-selling list of 300 pharma brands in the domestic market.

During the quarter the company launched seven new products key among these were the Cox 2 inhibitor for the treatment of arthritis, Rofact (rofecoxib), the type 2 oral antidiabetic Glypride (glimiperide), Nodict (naltrexone) for use in drug abuse treatments, the allergy treatment Fexotrol (fexofenadine). Milmet's range was enhanced with the addition of Azelast eyedrops (azelastine), and Ketorid eye drops (ketotifen).

The management has made a statement that their strategy of focus on niche specialty areas would continue in the near future too and they are confident of maintaining double the industry growth rate for the year.

The stock quotes at Rs 595, which discounts the annualised earnings by 21.4 times.


Equitymaster requests your view! Post a comment on "Sun Pharma: Continues to outpace industry". Click here!

  

More Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 18, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS